铁调素调节蛋白、骨形成蛋白6及铁调素在乳腺癌组织中的表达及其与贫血的关系

目的 研究乳腺癌组织中铁调素调节蛋白（hemojuvelin，HJV）、骨形成蛋白6（bone morphogenetic protein 6，bmp6）及铁调素（hepcidin）的表达的临床意义及和贫血的关系。方法 采用免疫组化方法对64例乳腺癌患者组织以及15例癌旁的正常乳腺组织中的铁调素调节蛋白、骨形成蛋白6及铁调素的表达情况进行检测，并分析上述指标之间的关系及其与患者临床特征、乳腺癌内分泌分型以及贫血的关系。结果 乳腺癌组织中铁调素表达阳性率为48.4%，明显高于癌旁组织（P<0.01）。铁调素调节蛋白、骨形成蛋白6的表达阳性率在乳腺癌组织中与癌旁组织比较，差异无统计学意义（P>0.05）。预后较好的luminal A型+luminal B型组中铁调素表达阳性率明显低于预后差的组；而铁调素调节蛋白、骨形成蛋白6的表达在两组无明显区别。铁调素的表达在ER阴性组中明显高于ER阳性组，而铁调素调节蛋白、骨形成蛋白6的表达在两组无明显区别。铁调素的表达与淋巴结转移有关，与患者的年龄、T分期无关，铁调素调节蛋白及骨形成蛋白6的表达与患者的年龄、T分期、和淋巴结转移均无关。铁调素调节蛋白、骨形成蛋白6的表达与铁调素无相关。贫血组与无贫血组患者铁调素调节蛋白、骨形成蛋白6及铁调素的表达无区别。结论 乳腺癌组织中铁调素的表达阳性率高于癌旁正常组织，铁调素的表达与乳腺癌内分泌分型及肿瘤的临床病理特征有关。乳腺癌组织中铁调素调节蛋白、骨形成蛋白6的表达与铁调素的表达无关。乳腺癌患者术前贫血与肿瘤组织中的铁调素、铁调素调节蛋白及骨形成蛋白6的表达无关。

Expression of Hemojuvelin, Bone Morphogenetic Protein 6 and Hepcidin in Breast Cancer, and its Relationship with Anemia

Objective To study the clinical significance of the expression of hemojuvelin (HJV), bone morphogenetic protein 6 (BMP6) and hepcidin in breast cancer tissues and its relationship with anemia.Methods Immuno-histochemical method was used to detect the expression of HJV, BMP6 and hepcidin in 64 cases of breast cancer patients and 15 cases of normal breast paracancer tissue.Results The expression rate of hepcidin in breast cancer tissues was 48.4%, which was higher than the expression rate in normal breast paracancer tissue (P<0.01), but the expression rate of HJV and BMP6 had not significant difference between the two groups. The expression rate of hepcidin in the group luminal A type and luminal B type which had better prognosis was obviously lower than the group HER-2(+) type and Basal-like type whose prognosis was poor, but the expression rate of HJV and BMP6 had no significant difference between the two groups. The expression rate of hepcidin in the group ER (-) was higher than the group ER (+), but the expression rate of HJV and BMP6 were not significant difference between the two groups. The expression of hepcidin was related to patient''s lymph node metastasis,but were not related to patient''s age and staging of tumor. The expression of HJV and BMP6 were not related to age, staging of tumor and lymph node metastasis. There expression of HJV and BMP6 was not correlated with hepcidin expression. There were no significant difference in the expression of HJV, BMP6 and hepcidin between anemia group and non-anemia group.Conclusion The expression rate of hepcidin in breast cancer tissues was higher than the expression in normal breast paracancer tissue. The expression of hepcidin was related to the clinical features and molecular characteristics-Based classification. The preoperative anemia in breast cancer patients was not related to the expression of HJV, BMP6 and hepcidin.